user

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

被引：7
|
作者：
Badros, Ashraf Z. [1 ]
Hyjek, Elizabeth [2 ]
Ma, Ning [1 ]
Lesokhin, Alexander M. [3 ]
Rapoport, Aaron P. [1 ]
Kocoglu, Mehmet H. [1 ]
Lederer, Emily [4 ]
Philip, Sunita [4 ]
Lesho, Patricia [4 ]
Johnson, Ashlee [4 ]
Dell, Cameron [4 ]
Goloubeva, Olga [4 ]
Singh, Zeba [5 ]
机构：
[1] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD USA
[2] Univ Chicago, Dept Pathol, Chicago, IL USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, New York, NY USA
[4] Univ Maryland, Baltimore, MD USA
[5] Univ Maryland, Sch Med, Pathol, Baltimore, MD USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.490.490
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
490
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [2] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [3] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [4] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [5] Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
    Farrell, James
    Bertin, Nicolas
    Fischer, Claire
    Gauthier, Aline
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S169 - S170
  • [6] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
    Ocio, E. M.
    Shah, J.
    Jagannath, S.
    Mateos, M-V
    Palumbo, A.
    Kher, U.
    Marinello, P.
    San Miguel, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [8] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [9] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [10] A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Kocoglu, Mehmet H.
    Ma, Ning
    Rapoport, Aaron P.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Dell, Cameron
    Hardy, Nancy M.
    Yared, Jean
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2015, 126 (23)
12345